News

News 07.12.2016 Neurimmune and TVM Capital Life Science’s latest fund, TVM Life Science Ventures VII, today announced their investment in AL-S Pharma AG, a company based in Schlieren/Zurich, Switzerland. AL-S Pharma will develop, to proof-of-concept, AP-101, a human monoclonal antibody targeting misfolded SOD1 for the treatment of amyotrophic lateral sclerosis (ALS) that...

External events 28.10.2016 Please find the link to the SECA event calendar below. SECA members and non-members are invited. (more…)

External events 28.10.2016 Event calendar of the Technoparks Zurich, Winterthur, Aargau, Luzern and Ticino. (more…)

Internal events
Event date: 23.01.2018 Krebs Cycle reprogrammed for Cytokines Luke O`Neill, Trinity College Dublin 11:30 a.m., seminar room, 4th floor, Wagistrasse 12 Luke O`Neill is professor of Biochemistry and Immunology at Trinity College in Dublin, Ireland. His research investigates molecular pathways of inflammation, in particular innate immune mechanisms. His work on activation and signaling pathways of toll-like receptors...

News 27.10.2016 Scientists at Neurimmune described results from the Phase 1b PRIME clinical trial of the monoclonal antibody aducanumab. The report, published in the journal Nature, showed that aducanumab removed amyloid plaques from the brains of patients with early-stage Alzheimer’s disease. Importantly, amyloid plaque reductions occurred in both a dose- and time-dependent manner. After...